The Opioids Market to grow with biosensors

The Opioids Market is ascertained to make greater strides in the future. The present-day and futuristic cutting-edge technology, namely IoT, AI, and Big Data operate better in a lightning-fast and reliable internet connection. The benefits of high-speed internet would be seen in telecare in the next 2-3 years, but going forward, more authentic data streams are likely to come up with better-connected devices, thereby revolutionizing the healthcare system.
Demand for synthetic opioids continues to witness a decline in North America. According to a new research from Persistence Market Research, the US$ 75 billion synthetic opioids market will grow at a sluggish 2.4% during the period 2016-2024.

Rising concerns about the addictive nature of opioids, combined with drug abuse has led to declining sales. According to the Centers for Disease Control and Prevention (CDC) around 33,000 Americans died from opioid overdose in 2015. The agency also reported that almost half of non-cancer patients who have been prescribed opioids for a month are still dependent on the pills a year later. Further, side effects of synthetic opioids, such as reduce , urinary difficulties, appetite loss, and spells of dizziness are also influencing sales negatively.

Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/15898

According to Persistence Market Research, introduction of non-abuse opioid drugs and drug exclusivity for branded options are the opportunities for pharmaceutical companies.

Get a Customized Scope to Match Your Need Ask an Expert- sales@persistencemarketresearch.com

Company Profiles:
Purdue Pharma LP
Pfizer Inc.
Janssen Pharmaceuticals, Inc.
Teva Pharmaceuticals
Endo International plc
West-Ward Pharmaceuticals (Hikma’s US subsidiary)
Mallinckrodt Pharmaceuticals plc
Mylan N.V.
Impax Laboratories, Inc
Indivior Plc.
Others.

Request for Methodology@ https://www.persistencemarketresearch.com/methodology/15898

Key Trends

Leading pharmaceutical companies are partnering with pain management service providers to boost sales.
Focus on developing non-addictive variants is growing, with leading players altering their packaging and drug formulation.
Pharmaceutical companies are promoting their novel products to cut down competition from generic manufacturers.
The Drug Enforcement Administration’s plan to reduce the amount of Schedule II opioid pain medication manufactured in the U.S. by 25% can significantly impact sales in foreseeable future.
Persistence Market Research’s study on the North America synthetic opioids market revealed that only 18% of opioids are obtained from licensed physicians. The report also found that increasing government regulations and DEA cuts can reduce unauthorized access.

By product type, the report has segmented the market into synthetic opioids and semi-synthetic opioids. Semi-synthetic opioids continue to witness heavy demand, accounting for nearly 92% value share in 2016. By sales, highest-selling semi-synthetic opioids are hydrocodone, oxycodone, and buprenorphine.

Access Full Report@ https://www.persistencemarketresearch.com/checkout/15898

Pain management remains the dominant application of synthetic opioids, accounting for over 90% revenue share of the market in 2016. Valued at over US$ 67 billion in 2016, use of synthetic opioids for pain management is expected to grow at 2.3% CAGR through 2024.

Retail outlets remain the dominant application segment for synthetic opioids, accounting for nearly 66% revenue share in 2016. Availability of synthetic opioids in retail outlets will continue to influence sales. By 2020, US$ 55 Bn worth of synthetic opioids will be sold through retail outlets in North America.

The U.S. remains at the forefront of global demand for opioids; unsurprisingly, it dominates the North America synthetic opioids market. Canada’s revenue share – 9.9% in 2016 – is projected to reach 10.6% by 2026.

Complete Report Details@ https://www.persistencemarketresearch.com/market-research/opioids-market.asp

Read More Trending "PMR Exclusive Article"-

Atrophic Scar Treatment Market@ https://www.persistencemarketresearch.com/market-research/atrophic-scar-treatment-market.asp

CAR T-Cell Therapy Market@ https://www.persistencemarketresearch.com/market-research/car-t-cell-therapy-market.asp

Contact Us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com
Website – https://www.persistencemarketresearch.com

About us-
Business intelligence is the foundation of every business model employed by Persistence Market Research. Multi-dimensional sources are being put to work, which include big data, customer experience analytics, and real-time data collection. Thus, working on “micros” by Persistence Market Research helps companies overcome their “macro” business challenges.

This release was published on openPR.